Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.
Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.
Moat: none
Headquarters: Boston, Massachusetts, US · Employees: 54
Size Seaport Therapeutics (SPTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $980M, the 2247th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.31 on 18 Nov 2026.
Performance Over six months the shares gained 16.0%, against -14.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Capital Return on invested capital runs 126.7 points below its cost of capital (20.0% WACC).
Short interest Short interest is 7.0% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | -$1.43M | -$1.41M | -$214,000 |
| EBITDA | -$149M | -$85.9M | -$52.2M |
| Net income | -$139M | -$74.9M | -$46.9M |
| Free cash flow | -$95.7M | -$78.3M | -$29.7M |
| Capital expenditure | $25,000 | $356,000 | $113,000 |
| Total debt | $4.69M | $5.08M | $5.01M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SPTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.0% | -7.6% | 9th highest of 21 |
| 6-month return | +16.0% | -14.5% | 4th highest of 21 |
| Distance from 52-week high | -35.5% | -36.6% | 11th highest of 21 |
| ROIC minus cost of capital | -126.7 pp | -0.4 pp | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 1.3× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | 75.0× | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | 4.7× | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 1.4× | 2.3% | +1.8% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 1.3× | n/a | n/a |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 0.9× | -10.7% | -7.0% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 2.3× | 4.3% | +3.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 4.0× | 7.5% | -4.5% |